

A multicentre study comparing treatment of patients with neuroendocrine gastro-entero-pancreatic tumours with 177Lu-octreotate versus combined 177Lu-octreotate and capecitabine treatment

Submission date 07/03/2007	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 07/03/2007	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 26/08/2021	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M van Essen

Contact details
Erasmus Medical Centre
Dr Molewaterplein 40
Rotterdam
Netherlands
3015 GD
+31 (0)10 463 5963
d.j.kwekkeboom@erasmusmc.nl

Additional identifiers

Protocol serial number
NL889 (NTR913)

Study information

Scientific Title

A multicentre study comparing treatment of patients with neuroendocrine gastro-entero-pancreatic tumours with ¹⁷⁷Lu-octreotate versus combined ¹⁷⁷Lu-octreotate and capecitabine treatment

Study objectives

Chemosensitisation with capecitabine improves the percentage of patients with objective tumour responses who are also treated with [¹⁷⁷Lu-DOTA0,Tyr3]octreotate.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Randomised, active controlled, parallel group, multicentre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Neuroendocrine gastro-entero-pancreatic tumours

Interventions

Arm one: Treatment with the radioactive somatostatin analogue [¹⁷⁷Lu-DOTA0,Tyr3]octreotate

Arm two: Treatment with [¹⁷⁷Lu-DOTA0,Tyr3]octreotate and capecitabine

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

[¹⁷⁷Lu-DOTA0,Tyr3]octreotate

Primary outcome(s)

Efficacy and safety assessments:

Objective response as determined by SWOG criteria is the main efficacy endpoint. Upon entry, subjects must have at least one measurable site of disease based on the SWOG response criteria. All lesions must be identified at baseline by physical exam, CT or Magnetic Resonance Imaging (MRI) within two months prior to the start of treatment. Changes from baseline will be assessed

six weeks after the last treatment, and three, six, and 12 months after the last treatment, and then every six months, until progression occurs. Patients who discontinue early due to clinical disease progression (unsatisfactory therapeutic effect) do not require a tumour assessment.

The overall survival of patients treated with radio-labelled somatostatin analogue will be calculated from the first day of treatment until the day of death. In patients who change to other anti-tumour treatments or who are lost to follow-up censored survival will be determined by the last regular visit. The time to progression is calculated from the first day of treatment to the day of documented progression.

Tumour Assessment/SWOG:

For CT imaging at entry, a triphasic, contrast enhanced study should be performed with a slice distance of 5 or 8 mm, and continuous slices. For follow-up CT imaging, triphasic imaging is not mandatory: the imaging phase at which the lesions are best recognised can be repeated instead.

Tumour response will be recorded according to the SWOG criteria by the investigators. Bidimensional tumour measurements from CT or MRI scans that were performed before treatment enrolment and after completing the therapy will be recorded.

End of Study:

The completion of the last day of the last study period or the date and reasons of premature discontinuation from the study will be recorded. End-point of the follow-up period is disease progression or death. The follow-up may be ended five years after the conclusion of treatment. However, in all patients the collection of toxicity data (haematology, renal function) should be continued either by the investigator, referring physician, or general practitioner.

Survival Information:

Information regarding the status of the patient, date of last contact or date of death will be collected.

Key secondary outcome(s))

1. Changes in serum chromogranin-A concentrations
2. Safety of treatment as measured by the rate of adverse events and the monitoring of selected laboratory evaluations
3. Effect of the different treatment arms on Quality of Life as measured by the EORTC QLQ-C30 questionnaire
4. Effects on Tumour Growth Rate (TGR)

Completion date

01/03/2010

Eligibility

Key inclusion criteria

1. Presence of histology proven Gastro-Entero-Pancreatic (GEP) tumour(s), including bronchial carcinoids
2. Presence of somatostatin-receptors on the known tumour lesions demonstrated by OctreoScan® within six months of the first dose of radio-labelled octreotate/octreotide. The uptake on the OctreoScan® should be at least as high as normal liver uptake on planar imaging
3. Life expectancy greater than 12 weeks
4. Serum creatinine less than 150 µmol/litre or 1.7 mg/dL, and a measured creatinine

clearance (or measured Glomerular Filtration Rate [GFR] using plasma clearance methods, not gamma-camera based) of greater than or equal to 50 mL/min

5. Haemoglobin (Hgb) concentration greater than or equal to 5.5 mmol/L (greater than or equal to 8.9 g/dL); White Blood Cells (WBC) greater than or equal to $2 \times 10^9/L$ (2000/mm³); platelets greater than or equal to $100 \times 10^9/L$ ($100 \times 10^3/mm^3$)
6. Total bilirubin less than 3 x Upper Limit of Normal (ULN)
7. Serum albumin less than 30 g/L, or serum albumin greater than or equal to 30 g/L but normal prothrombin time
8. Karnofsky Performance Status greater than or equal to 60
9. Presence of at least one measurable site of disease
10. Patient's written voluntary informed consent to participate in the study, obtained prior to enrolment into the study. The informed consent must be maintained in the investigator's study files

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Possible surgery with curative intent
2. Surgery, radiotherapy, chemotherapy, or other investigational therapy within three months of the start of therapy
3. Patients with known brain metastases unless these metastases have been treated and stabilised for at least six months prior to study start. Patients with a history of brain metastases must have a head Computed Tomography (CT) with contrast to document stable disease prior to study start
4. Uncontrolled congestive heart failure
5. Any subject who is taking concomitant medications which decrease renal function (such as aminoglycoside antibiotics)
6. Any subject receiving therapy with somatostatin analogues, unless the dose has been stable for at least three months prior to the first cycle in this study and the disease status during these three months has been documented by South West Oncology Group (SWOG) criteria as described in this study
7. Any subject receiving therapy with short-acting somatostatin analogues in whom these analogues cannot be interrupted for 12 hours before and 12 hours after the administration of the radio-labelled somatostatin analogues, or any subject receiving therapy with long-acting somatostatin analogues in whom these analogues cannot be interrupted for at least six weeks before the administration of the radio-labelled somatostatin analogues, unless the uptake on the OctreoScan® during continued somatostatin analogue medication is at least as high as normal liver uptake on planar imaging
8. In patients with unusual haematological parameters, including an increased Mean red Cell Volume (MCV) (greater than 105 fL), and especially in those who had previous chemotherapy, the advice of a haematologist should be sought, for adequate further work-up

- 9. Subjects with another significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study
- 10. Pregnancy
- 11. Prior radiation therapy to more than 25% of the bone marrow

Date of first enrolment

01/03/2007

Date of final enrolment

01/03/2010

Locations

Countries of recruitment

Netherlands

Study participating centre

Erasmus Medical Centre

Rotterdam

Netherlands

3015 GD

Sponsor information

Organisation

Erasmus Medical Centre (The Netherlands)

ROR

<https://ror.org/018906e22>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Erasmus Medical Centre (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes